 PENNINGTON, N.J. and SAN DIEGO, April 14, 2021 PRNewswire -- OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec, a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it has received authorization to CE mark its proprietary next generation go-to-market gene delivery device, GenPulseTM, a part of the OncoSec Medical System OMS electroporation device platform for use in solid tumors. 